MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

New treatment option will reduce cardiovascular risk for the up-to-44 per cent of patients who cannot tolerate ACE inhibitors

MICARDIS(R) (telmisartan) has received Health Canada approval to reduce the risk of non-fatal stroke or non-fatal myocardial infarction in..Next..